Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting

Phase 2

Talazoparib & TemozolomideTalazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT03672773

Conditions

Recurrent Extensive Stage Small Cell Lung Carcinoma

Refractory Extensive Stage Small Cell Lung Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Talazoparib

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2025-03-25.